DexCom (NASDAQ:DXCM) had its price objective increased by Jefferies Financial Group to $148.00 in a research report report published on Wednesday, The Fly reports. The brokerage currently has a buy rating on the medical device company’s stock. Jefferies Financial Group also issued estimates for DexCom’s Q4 2018 earnings at $0.17 EPS, FY2018 earnings at ($0.09) EPS, Q1 2019 earnings at $0.00 EPS, Q2 2019 earnings at $0.19 EPS, Q3 2019 earnings at $0.00 EPS, Q4 2019 earnings at $0.21 EPS, FY2019 earnings at $0.40 EPS and FY2020 earnings at $0.30 EPS.
DXCM has been the topic of a number of other reports. Northland Securities raised shares of DexCom from an under perform rating to a market perform rating in a research note on Wednesday, September 12th. Stephens raised their price objective on shares of DexCom from $135.00 to $160.00 and gave the company an overweight rating in a research note on Thursday, August 23rd. Canaccord Genuity raised their price objective on shares of DexCom from $125.00 to $150.00 and gave the company a buy rating in a research note on Thursday, August 23rd. Piper Jaffray Companies raised their price objective on shares of DexCom to $150.00 and gave the company an overweight rating in a research note on Thursday, August 2nd. Finally, BidaskClub raised shares of DexCom from a buy rating to a strong-buy rating in a research note on Tuesday, August 21st. Seven analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $132.50.
NASDAQ DXCM traded up $1.05 on Wednesday, hitting $149.46. 1,594,508 shares of the company were exchanged, compared to its average volume of 1,254,658. The firm has a market cap of $12.85 billion, a PE ratio of -257.69 and a beta of 0.60. DexCom has a 12 month low of $49.80 and a 12 month high of $152.14. The company has a quick ratio of 4.62, a current ratio of 4.71 and a debt-to-equity ratio of 0.60.
In other news, CEO Kevin R. Sayer sold 11,161 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $123.22, for a total value of $1,375,258.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Andrew K. Balo sold 5,000 shares of the stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $124.25, for a total transaction of $621,250.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 157,892 shares of company stock valued at $21,864,030. 1.80% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the company. Stratos Wealth Partners LTD. purchased a new stake in shares of DexCom in the third quarter valued at about $124,000. Clinton Group Inc. purchased a new stake in shares of DexCom in the second quarter valued at about $201,000. IBM Retirement Fund purchased a new stake in shares of DexCom in the third quarter valued at about $203,000. Brighton Jones LLC purchased a new stake in shares of DexCom in the third quarter valued at about $204,000. Finally, Strs Ohio purchased a new stake in shares of DexCom in the third quarter valued at about $213,000.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.